GSK reported turnover of £7.6 billion in Q1 2026, representing a 5% year-on-year (YOY) increase at constant currencies, reflecting continued growth across its core business segments.
Core operating profit increased 6% at constant currencies, while core earnings per share (EPS) grew 4% to 46.5 pence, demonstrating sustained profitability alongside revenue expansion.
Growth in the quarter was driven by specialty medicines (£3.23 billion) and strong vaccine performance, with Shingrix generating £1.03 billion, highlighting continued demand for key assets.
Pipeline progression remained a key focus, with bepirovirsen advancing in the Phase III B-Well-1 and B-Well-2 trials in chronic hepatitis B. Additional development programmes include camlipixant in chronic cough and ongoing expansion studies for Jemperli in oncology, alongside long-acting HIV prevention studies.
GSK expects multiple late-stage trial readouts and up to 10 Phase III trial starts in 2026, reinforcing continued pipeline momentum.
The company reaffirmed its 2026 guidance, expecting turnover growth of 3% to 5% and core operating profit growth of 7% to 9% at constant currencies.
The performance reflects GSK’s strategy of focusing on specialty medicines, vaccines, and high-value pipeline assets, while advancing late-stage programmes to drive future growth.
Looking ahead, upcoming clinical trial readouts, regulatory progress, and continued strong demand for key brands are expected to support potential growth in the coming quarters, with pipeline assets contributing to future revenue expansion.
